Please login to the form below

Not currently logged in
Email:
Password:

Solymbic

This page shows the latest Solymbic news and features for those working in and with pharma, biotech and healthcare.

Amgen wins European approval for Humira biosimilar Amgevita

Amgen wins European approval for Humira biosimilar Amgevita

Meanwhile, in Europe Amgen’s new product has a duplicate marketing authorisation under the brand name Solymbic.

Latest news

  • Merck confirms sale of biosimilar division Merck confirms sale of biosimilar division

    In January, the EMA's Committee for Medicinal Products for Human Use (CHMP) backed approval of the Humira biosimilar under two brand names - Amgevita and Solymbic – with approval expected in the

  • Amgen's Humira biosimilars backed for EU approval Amgen's Humira biosimilars backed for EU approval

    Amgevita and Solymbic prepare to challenge AbbVie’s blockbuster. AbbVie's Humira (adalimumab) looks set to be on the defensive in Europe as well as the US this year, after the ... Amgen's biosimilars - Amgevita (ABP 501) and Solymbic - were recommended

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
COUCH.

WE ARE COUCH – a full service medical communications agency. We are a trusted partner; always striving to help make...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics